Page last updated: 2024-10-29

ketoconazole and Epithelial Ovarian Cancer

ketoconazole has been researched along with Epithelial Ovarian Cancer in 1 studies

1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.

Research Excerpts

ExcerptRelevanceReference
"Epithelial ovarian cancer remains the most devastating gynecologic cancer with drug resistance and rapid recurrence."1.43Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells. ( Hiramatsu, Y; Masuyama, H; Nakamura, K; Nobumoto, E, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Masuyama, H1
Nakamura, K1
Nobumoto, E1
Hiramatsu, Y1

Other Studies

1 other study available for ketoconazole and Epithelial Ovarian Cancer

ArticleYear
Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
    International journal of oncology, 2016, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Ovarian Epithelial;

2016